#SDG 2 Treatment of Anaemia | Food Supplement RUBENFLUX®
06/07/2020
Inside the 2nd United Nations' SDG Goal: END HUNGER, ACHIEVE FOOD SECURITY AND IMPROVED
NUTRITION AND PROMOTE SUSTAINABLE AGRICULTURE, there is a particular Target 2.2, aimed at ending all forms of malnutrition, and addressing the nutritional needs of adolescent girls, pregnant and lactating women and older persons. Within the Global indicator framework for the Sustainable Development Goals and targets of the 2030 Agenda for Sustainable Development, a particular attention is given to a specific KPI “Prevalence of anaemia in women aged 15 to 49 years, by pregnancy status (percentage)”.

Our product RUBENFLUX® is a dietary supplement of essential amino acids, vitamin C, Group B vitamins and iron, for the female market, indicated for the red blood cells and hemoglobin natural formation and for the reduction of tiredness and fatigue. The RUBENFLUX® formulation, supported by clinical trials, scientific publications and granted with an IP by the Italian Patent office, is developed following the basis of Physiological Modulation.

RUBENFLUX® is proposed for on-demand production, international licensing and/or definitive purchase for those Companies strategically involved in the treatment of anaemia, directly or through commercial activities.

For further information/queries please contact: info@blymum.com  
REGULATORY COMPLIANCE SERVICES | Smart Wellbeing Modulations
08/06/2020
Recently, we have drawn up and followed the submission, through an international recognized patent office, of a third party’s patent application pertaining to a Class III medical device to treat Obstructive Sleep Apnea (OSA). The patent application has successfully been published last July 2019 and is currently being finally approved and released by the European Patent Office (EPO) as an official intellectual property.

If new Clients wish us to assist them in studying, drafting and deposit new IPs, we will be proud to assist them with dossier filing, technical support, and regulatory compliance.


For more information contact: info@blymum.com

Image courtesy of Danilo Rizzuti at FreeDigitalPhotos.net
CLINICAL TRIALS MANAGEMENT | Class III Medical Device
06/05/2020
In the past 20 Years the members of our Team have developed a substantial clinical experience with slimming products (food supplements and medical devices) which is constantly at Your disposal for future investigations.

This May 2020 Blymum has started a new clinical trial management together with both the University of Pavia and the University of Milan. A 3-month randomized double blind placebo-controlled investigation with 120 subjects has been successfully designed and implemented. The aim of the study is to assess the ability of a German made class III Medical Device, marketed in 47 countries Worldwide, to reduce/manage weight. The enrollment is currently underway.

We carry out Clinical Trials Design & Project Management activities, throughout all key phases: Experimental Design; Dossier Set-up; Participant Enrollment; Treatment & Monitoring Support; Clinical Data Management.

Our distinctive Clinical Trials Management timeframe can be easily applied to any Class III Medical Device.

For more information contact: info@blymum.com 
LILLA LINE INTERNATIONAL LICENSING & ACQUISITIONS
02/03/2020
BLYMUM is proposing the LILLA LINE whole portfolio or eventually single products for international licensing and/or for definitive purchase. In case of products/portfolio acquisition, the product’s formula dossier, product samples, literature dossier, IP transfer (if available), testing dossier (if available), and supporting marketing and training contents are delivered.

For more information please contact info@blymum.com